文献速递鼻科

手术治疗的慢性鼻窦炎SNOT-22症状域最小临床重要差异研究

Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2017-10-20

本研究为前瞻性多中心观察队列的二次分析,纳入276例药物难治性慢性鼻窦炎手术患者,采用分布法计算SNOT-22总量表及5个症状域的MCID,总量表平均MCID为9.0,各域为2.4-3.9;基于SF-6D的锚定法预测准确性弱。

要点

  • SNOT-22总量表平均MCID为9.0,与既往指标一致。
  • 鼻科、鼻外鼻科、耳面部、心理、睡眠域MCID分别为3.8、2.4、3.2、3.9、2.9。
  • 基于SF-6D的锚定法ROC曲线下面积≤0.71,关联较弱。

核心结论

  • SNOT-22各症状域MCID的估计值有助于改善鼻科结局研究的临床解读。

研究设计与样本

  • 研究为前瞻性多中心观察队列的二次分析,共纳入276例药物难治性慢性鼻窦炎手术患者。

主要发现

  • 分布法计算的总SNOT-22平均MCID为9.0,与既往发表指标一致。
  • 鼻科域MCID为3.8,鼻外鼻科域为2.4,耳面部域为3.2,心理域为3.9,睡眠域为2.9。
  • 基于SF-6D的锚定法在总量表和各域ROC曲线下面积≤0.71,预测准确性不强。

关键数值与推荐

  • 总SNOT-22平均MCID为9.0。
  • 鼻科域MCID为3.8,鼻外鼻科域为2.4,耳面部域为3.2,心理域为3.9,睡眠域为2.9。
  • 基于SF-6D的锚定法ROC曲线下面积≤0.71。

临床怎么用

  • 临床中可参考各症状域MCID值解读SNOT-22评分变化,判断手术疗效。

局限性

  • 基于SF-6D的锚定法预测准确性较弱,ROC曲线下面积≤0.71。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior work has described 5 domains within the 22-item Sino-Nasal Outcomes Test (SNOT-22) that allow for stratification of symptoms into similar clusters and that can be used to direct therapy. Although the outcomes of various interventions on these symptom domains have been reported, minimal clinically important difference (MCID) values have not been investigated, which has limited clinical interpretation of these results. METHODS: This study was designed as a secondary analysis of a prospective, multi-institutional, observational cohort. A total of 276 patients with medically refractory CRS who underwent surgical management were enrolled. Distribution-based methods (half-standard deviation, standard error of measurement, Cohen's d, and the minimum detectable change) were used to compute MCID values for both SNOT-22 total and domain scores. The Medical Outcomes Study Short Form 6D (SF-6D) health utility score was used to operationalize anchor-based associations using receiver-operating characteristic (ROC) curves. RESULTS: The mean MCID of several distribution-based methods for total SNOT-22 scores was 9.0, in agreement with previously published metrics. Average MCID values for the rhinologic, extranasal rhinologic, ear/facial, psychological, and sleep domain scores were 3.8, 2.4, 3.2, 3.9, and 2.9, respectively. Anchor-based approaches with the SF-6D did not have strong predictive accuracy across total SNOT-22 scores or domains (ROC areas under-the-curve ≤ 0.71), indicating weak associations between improvement in SNOT-22 scores and health utility as measured by the SF-6D. CONCLUSION: This estimation of MCID values for the SNOT-22 symptom domains allows for improved clinical interpretation of results from past, present, and future rhinologic outcomes research.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017. PMID: 29053911. doi:10.1002/alr.22028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。